<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Bromocriptine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01200</strong>&#160; (APRD00622)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational</td></tr><tr><th>Description</th><td><p>Bromocriptine mesylate is a semisynthetic ergot alkaloid derivative with potent dopaminergic activity. It is indicated for the management of signs and symptoms of Parkinsonian Syndrome. Bromocriptine also inhibits prolactin secretion and may be used to treat dysfunctions associated with hyperprolactinemia. It also causes sustained suppression of somatotropin (growth hormone) secretion in some patients with acromegaly. Bromocriptine has been associated with pulmonary fibrosis.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01200/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01200/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01200.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01200.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01200.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01200.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01200.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01200">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>2-bromo-&#945;-ergocryptine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>2-bromo-&#945;-ergokryptin</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>2-bromo-&#945;-ergokryptine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Bromocriptina</td><td>Spanish</td><td>INN</td></tr><tr><td>Bromocriptinum</td><td>Latin</td><td>INN</td></tr><tr><td>Bromocryptine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Bromoergocriptine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Bromoergocryptine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Apo-Bromocriptine</td><td>Apotex</td></tr><tr><td>Bagren</td><td>Serono (Brazil)</td></tr><tr><td>CYCLOSET</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Ergoset</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Parlodel</td><td>Novartis</td></tr><tr><td>Parlodel Snaptabs</td><td>Novartis</td></tr><tr><td>Pravidel</td><td>Meda (Germany, Sweden), Novartis (Canada, discontinued)</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/hormone-antagonists">Hormone Antagonists</a></li>
<li><a href="/mesh/antiparkinson-agents">Antiparkinson Agents</a></li>
<li><a href="/mesh/dopamine-agonists">Dopamine Agonists</a></li>
<li><a href="/mesh/antidyskinetics">Antidyskinetics</a></li></ul></td></tr><tr><th>CAS number</th><td>25614-03-3</td></tr><tr><th>Weight</th><td>Average: 654.595<br>Monoisotopic: 653.221282062</td></tr><tr><th>Chemical Formula</th><td>C<sub>32</sub>H<sub>40</sub>BrN<sub>5</sub>O<sub>5</sub></td></tr><tr><th>InChI Key</th><td>OZVBMTJYIDMWIL-AYFBDAFISA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C32H40BrN5O5/c1-16(2)12-24-29(40)37-11-7-10-25(37)32(42)38(24)30(41)31(43-32,17(3)4)35-28(39)18-13-20-19-8-6-9-22-26(19)21(27(33)34-22)14-23(20)36(5)15-18/h6,8-9,13,16-18,23-25,34,42H,7,10-12,14-15H2,1-5H3,(H,35,39)/t18-,23-,24+,25+,31-,32+/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(4R,7R)-10-bromo-N-[(1S,2S,4R,7S)-2-hydroxy-7-(2-methylpropyl)-5,8-dioxo-4-(propan-2-yl)-3-oxa-6,9-diazatricyclo[7.3.0.0^{2,6}]dodecan-4-yl]-6-methyl-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),2,9,12,14-pentaene-4-carboxamide</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12CCCN1C(=O)[C@H](CC(C)C)N1C(=O)[C@](NC(=O)[C@H]3CN(C)[C@]4([H])CC5=C(Br)NC6=CC=CC(=C56)C4=C3)(O[C@@]21O)C(C)C</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Alkaloids and Derivatives</td></tr><tr><th>Class</th><td>Ergolines and Derivatives</td></tr><tr><th>Subclass</th><td>Lysergic Acids and Derivatives</td></tr><tr><th>Direct parent</th><td>Ergopeptines</td></tr><tr><th>Alternative parents</th><td>Cyclic Peptides; Indoloquinolines; Benzoquinolines; N-acyl-alpha Amino Acids and Derivatives; Pyrroloquinolines; Quinoline Carboxamides; N-substituted Nicotinamides; Isoindoles and Derivatives; Indoles; Tetrahydropyridines; Oxazolidinediones; Benzene and Substituted Derivatives; Piperazines; Diazinanes; Substituted Pyrroles; Aryl Bromides; Pyrrolidines; Tertiary Carboxylic Acid Amides; Secondary Carboxylic Acid Amides; Tertiary Amines; Polyamines; Enolates; Carboxylic Acids; Ethers; Organobromides; Ergoline Derivatives</td></tr><tr><th>Substituents</th><td>cyclic alpha peptide; ergoline skeleton; indoloquinoline; benzoquinoline; pyrroloquinoline; n-acyl-alpha amino acid or derivative; quinoline-3-carboxamide; n-substituted nicotinamide; quinoline; indole; isoindole or derivative; indole or derivative; tetrahydropyridine; oxazolidinedione; benzene; aryl halide; 1,4-diazinane; piperazine; substituted pyrrole; aryl bromide; pyrrolidine; pyrrole; tertiary carboxylic acid amide; carboxamide group; secondary carboxylic acid amide; tertiary amine; polyamine; carboxylic acid; ether; enolate; carboxylic acid derivative; organohalogen; organobromide; organonitrogen compound; amine</td></tr><tr><th>Classification description</th><td>This compound belongs to the ergopeptines. These are ergoline derivatives that contain a tripeptide structure attached to the basic ergoline ring in the same location as the amide group of the lysergic acid derivatives.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of galactorrhea due to hyperprolactinemia, prolactin-dependent menstrual disorders and infertility, prolactin-secreting adenomas, prolactin-dependent male hypogonadism, as adjunct therapy to surgery or radiotherapy for acromegaly or as monotherapy is special cases, as monotherapy in early Parksinsonian Syndrome or as an adjunct with levodopa in advanced cases with motor complications. Bromocriptine has also been used off-label to treat restless legs syndrome and neuroleptic malignant syndrome.</td></tr><tr><th>Pharmacodynamics</th><td>Bromocriptine stimulates centrally-located dopaminergic receptors resulting in a number of pharmacologic effects. Five dopamine receptor types from two dopaminergic subfamilies have been identified. The dopaminergic D1 receptor subfamily consists of D<sub>1</sub> and D<sub>5</sub> subreceptors, which are associated with dyskinesias. The dopaminergic D2 receptor subfamily consists of D<sub>2</sub>, D<sub>3</sub> and D<sub>4</sub> subreceptors, which are associated with improvement of symptoms of movement disorders. Thus, agonist activity specific for D2 subfamily receptors, primarily D<sub>2</sub> and D<sub>3</sub> receptor subtypes, are the primary targets of dopaminergic antiparkinsonian agents. It is thought that postsynaptic D<sub>2</sub> stimulation is primarily responsible for the antiparkinsonian effect of dopamine agonists, while presynaptic D<sub>2</sub> stimulation confers neuroprotective effects. This semisynthetic ergot derivative exhibits potent agonist activity on dopamine D<sub>2</sub>-receptors. It also exhibits agonist activity (in order of decreasing binding affinity) on 5-hydroxytryptamine (5-HT)<sub>1D</sub>, dopamine D<sub>3</sub>, 5-HT<sub>1A</sub>, 5-HT<sub>2A</sub>, 5-HT<sub>1B</sub>, and 5-HT<sub>2C</sub> receptors, antagonist activity on &#945;<sub>2A</sub>-adrenergic, &#945;<sub>2C</sub>, &#945;<sub>2B</sub>, and dopamine D<sub>1</sub> receptors, partial agonist activity at receptor 5-HT<sub>2B</sub>, and inactivates dopamine D<sub>4</sub> and 5-HT<sub>7</sub> receptors. Parkinsonian Syndrome manifests when approximately 80% of dopaminergic activity in the nigrostriatal pathway of the brain is lost. As this striatum is involved in modulating the intensity of coordinated muscle activity (e.g. movement, balance, walking), loss of activity may result in dystonia (acute muscle contraction), Parkinsonism (including symptoms of bradykinesia, tremor, rigidity, and flattened affect), akathesia (inner restlessness), tardive dyskinesia (involuntary muscle movements usually associated with long-term loss of dopaminergic activity), and neuroleptic malignant syndrome, which manifests when complete blockage of nigrostriatal dopamine occurs. High dopaminergic activity in the mesolimbic pathway of the brain causes hallucinations and delusions; these side effects of dopamine agonists are manifestations seen in patients with schizophrenia who have overractivity in this area of the brain. The hallucinogenic side effects of dopamine agonists may also be due to 5-HT<sub>2A</sub> agonism. The tuberoinfundibular pathway of the brain originates in the hypothalamus and terminates in the pituitary gland. In this pathway, dopamine inhibits lactotrophs in anterior pituitary from secreting prolactin. Increased dopaminergic activity in the tuberoinfundibular pathway inhibits prolactin secretion making bromocriptine an effective agent for treating disorders associated with hypersecretion of prolactin. Pulmonary fibrosis may be associated bromocriptine&#8217;s agonist activity at 5-HT<sub>1B</sub> and 5-HT<sub>2B</sub> receptors. </td></tr><tr><th>Mechanism of action</th><td>The dopamine D<sub>2</sub> receptor is a 7-transmembrane G-protein coupled receptor associated with G<sub>i</sub> proteins. In lactotrophs, stimulation of dopamine D<sub>2</sub> receptor causes inhibition of adenylyl cyclase, which decreases intracellular cAMP concentrations and blocks IP3-dependent release of Ca<sup>2+</sup> from intracellular stores. Decreases in intracellular calcium levels may also be brought about via inhibition of calcium influx through voltage-gated calcium channels, rather than via inhibition of adenylyl cyclase. Additionally, receptor activation blocks phosphorylation of p42/p44 MAPK and decreases MAPK/ERK kinase phosphorylation. Inhibition of MAPK appears to be mediated by c-Raf and B-Raf-dependent inhibition of MAPK/ERK kinase. Dopamine-stimulated growth hormone release from the pituitary gland is mediated by a decrease in intracellular calcium influx through voltage-gated calcium channels rather than via adenylyl cyclase inhibition. Stimulation of dopamine D<sub>2</sub> receptors in the nigrostriatal pathway leads to improvements in coordinated muscle activity in those with movement disorders. </td></tr><tr><th>Absorption</th><td>Approximately 28% of the oral dose is absorbed; however due to a substantial first pass effect, only 6% of the oral dose reaches the systemic circulation unchanged. Bromocriptine and its metabolites appear in the blood as early as 10 minutes following oral administration and peak plasma concentration are reached within 1-1.5 hours. Serum prolactin may be decreased within 2 hours or oral administration with a maximal effect achieved after 8 hours. Growth hormone concentrations in patients with acromegaly is reduced within 1-2 hours with a single oral dose of 2.5 mg and decreased growth hormone concentrations persist for at least 4-5 hours. </td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>90-96% bound to serum albumin</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Completely metabolized by the liver, primarily by hydrolysis of the amide bond to produce lysergic acid and a peptide fragment, both inactive and non-toxic. Bromocriptine is metabolized by cytochrome P450 3A4 and excreted primarily in the feces via biliary secretion. </p></td></tr><tr><th>Route of elimination</th><td>Parent drug and metabolites are almost completely excreted via the liver, and only 6% eliminated via the kidney.</td></tr><tr><th>Half life</th><td>2-8 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Symptoms of overdosage include nausea, vomiting, and severe hypotension. The most common adverse effects include nausea, headache, vertigo, constipation, light-headedness, abdominal cramps, nasal congestion, diarrhea, and hypotension. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.915</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              -
        </td>
        <td>0.9845</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.6618</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.8881</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8563</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.8388</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.837</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.8345</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7454</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9031</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.8326</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.8994</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Inhibitor</td>
        <td>0.796</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.5149</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.7879
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9353
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9973
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.7499 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9313
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.5
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Lek pharmaceutical and chemical co dd</li>
<li>Mylan pharmaceuticals inc</li>
<li>Zydus pharmaceuticals usa inc</li>
<li>Novartis pharmaceuticals corp</li>
<li>Lek pharmaceuticals d d</li>
<li>Paddock laboratories inc</li>
<li>Veroscience llc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.amerisourcebergen.com">Amerisource Health Services Corp.</a></li>
<li>Cadila Healthcare Ltd.</li>
<li>Heartland Repack Services LLC</li>
<li>Kaiser Foundation Hospital</li>
<li><a href="http://www.lek.si">Lek Pharmaceuticals Inc.</a></li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.unitdosesupply.com">Murfreesboro Pharmaceutical Nursing Supply</a></li>
<li><a href="http://www.mylan.com">Mylan</a></li>
<li><a href="http://www.novartis.com">Novartis AG</a></li>
<li><a href="http://www.paddocklabs.com">Paddock Labs</a></li>
<li>Pharmaceutical Utilization Management Program VA Inc.</li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li><a href="http://www.poli.it">Poli Industria Chimica SPA</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://www.sandoz.ca">Sandoz</a></li>
<li><a href="http://www.zydususa.com">Zydus Pharmaceuticals</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td>5 mg</td></tr><tr><td>Tablet</td><td>Oral</td><td>2.5 mg</td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01063">Acetophenazine</a></td><td>The phenothiazine decreases the effect of bromocriptine</td></tr><tr><td><a href="/drugs/DB01246">Alimemazine</a></td><td>The phenothiazine decreases the effect of bromocriptine</td></tr><tr><td><a href="/drugs/DB00477">Chlorpromazine</a></td><td>The phenothiazine decreases the effect of bromocriptine</td></tr><tr><td><a href="/drugs/DB06700">Desvenlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Erythromycin increases serum levels of bromocriptine</td></tr><tr><td><a href="/drugs/DB00392">Ethopropazine</a></td><td>The phenothiazine decreases the effect of bromocriptine</td></tr><tr><td><a href="/drugs/DB00623">Fluphenazine</a></td><td>The phenothiazine decreases the effect of bromocriptine</td></tr><tr><td><a href="/drugs/DB01321">Josamycin</a></td><td>Erythromycin increases serum levels of bromocriptine</td></tr><tr><td><a href="/drugs/DB00933">Mesoridazine</a></td><td>The phenothiazine decreases the effect of bromocriptine</td></tr><tr><td><a href="/drugs/DB00902">Methdilazine</a></td><td>The phenothiazine decreases the effect of bromocriptine</td></tr><tr><td><a href="/drugs/DB01403">Methotrimeprazine</a></td><td>The phenothiazine decreases the effect of bromocriptine</td></tr><tr><td><a href="/drugs/DB01267">Paliperidone</a></td><td>The atypical antipsychotic agent, paliperidone, may decrease the therapeutic effect of the anti-Parkinson's agent, bromocriptine. This interaction may be due to the dopamine antagonist properties of paliperidone. Consider an alternate antipsychotic in those with Parkinson's disease or consider using clozapine or quetiapine if an atypical antipsychotic is necessary. </td></tr><tr><td><a href="/drugs/DB00850">Perphenazine</a></td><td>The phenothiazine decreases the effect of bromocriptine</td></tr><tr><td><a href="/drugs/DB00397">Phenylpropanolamine</a></td><td>The sympathomimetic, phenylpropanolamine, increases the toxicity of bromocriptine.</td></tr><tr><td><a href="/drugs/DB00433">Prochlorperazine</a></td><td>The phenothiazine decreases the effect of bromocriptine</td></tr><tr><td><a href="/drugs/DB00420">Promazine</a></td><td>The phenothiazine decreases the effect of bromocriptine</td></tr><tr><td><a href="/drugs/DB01069">Promethazine</a></td><td>The phenothiazine decreases the effect of bromocriptine</td></tr><tr><td><a href="/drugs/DB00777">Propiomazine</a></td><td>The phenothiazine decreases the effect of bromocriptine</td></tr><tr><td><a href="/drugs/DB00852">Pseudoephedrine</a></td><td>The sympathomimetic, pseudoephedrine, increases the toxicity of bromocriptine.</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Bromocriptine may increase the blood concentration of Tacrolimus. Monitor for changes in the therapeutic/toxic effects of Tacrolimus if Bromocriptine therapy is initiated, discontinued or altered.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Telithromycin may reduce clearance of Bromocriptine. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Bromocriptine if Telithromycin is initiated, discontinued or dose changed.</td></tr><tr><td><a href="/drugs/DB00372">Thiethylperazine</a></td><td>The phenothiazine decreases the effect of bromocriptine</td></tr><tr><td><a href="/drugs/DB00679">Thioridazine</a></td><td>The phenothiazine decreases the effect of bromocriptine</td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>Thiothixene may antaonize the effects of the anti-Parkinsonian agent, Bromocriptine. Consider alternate therapy or monitor for decreased effects of both agents. </td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Tipranavir may increase the plasma concentration of Bromocriptine. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00193">Tramadol</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00752">Tranylcypromine</a></td><td>Increased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome. </td></tr><tr><td><a href="/drugs/DB00656">Trazodone</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00831">Trifluoperazine</a></td><td>The phenothiazine decreases the effect of bromocriptine</td></tr><tr><td><a href="/drugs/DB00508">Triflupromazine</a></td><td>The phenothiazine decreases the effect of bromocriptine</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome. </td></tr><tr><td><a href="/drugs/DB00285">Venlafaxine</a></td><td>Increased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.</td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Voriconazole may increase the serum concentration of bromocriptine likely by decreasing its metabolism. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00246">Ziprasidone</a></td><td>The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, bromocriptine. Consider alternate therapy or monitor for worsening of movement disorder. </td></tr><tr><td><a href="/drugs/DB00315">Zolmitriptan</a></td><td>Concomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, bromocriptine, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. 
Use of two serotonin modulators, such as zolmitriptan and bromocriptine, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.</td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and bromocriptine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.</td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and bromocriptine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.</td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Antagonism may occur between zuclopenthixol, a dopamine D2 receptor antagonist, and bromocriptine, a dopamine agonist. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of both agents if concurrent therapy is initiated, discontinued or dose(s) changed.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li>
<li>Take with food to reduce irritation.</li></ul></td></tr></tbody></table>